Hasil Pencarian - A Chari

Perbaiki Hasil
  1. 1
    Efficacy and Durability of Intratympanic Gentamicin Treatment for Meniere's Disease

    Efficacy and Durability of Intratympanic Gentamicin Treatment for Meniere's Disease oleh Yafeng Guan, Divya A. Chari, Divya A. Chari, Divya A. Chari, Divya A. Chari, Yu-Hsi Liu, Steven D. Rauch, Steven D. Rauch

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    New phase change nanomaterial for solar use: synthesis and characterization

    New phase change nanomaterial for solar use: synthesis and characterization oleh L Maifi, K Agroui, O Hioual, A Chari, T Karbache

    Diterbitkan 2022-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Music Engineering as a Novel Strategy for Enhancing Music Enjoyment in the Cochlear Implant Recipient

    Music Engineering as a Novel Strategy for Enhancing Music Enjoyment in the Cochlear Implant Recipient oleh Gavriel D. Kohlberg, Dean M. Mancuso, Divya A. Chari, Anil K. Lalwani

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Reverse Correlation Characterizes More Complete Tinnitus Spectra in Patients

    Reverse Correlation Characterizes More Complete Tinnitus Spectra in Patients oleh Nelson V. Barnett, Alec Hoyland, Divya A. Chari, Benjamin Parrell, Adam C. Lammert

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Comparative utility of vestibular function tests in patients with peripheral and central vestibular dysfunction

    Comparative utility of vestibular function tests in patients with peripheral and central vestibular dysfunction oleh Cameron B. Fattahi, Christopher Zaro, Janice J. Chung, Richard F. Lewis, Divya A. Chari

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence

    Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence oleh J. Martinez-Lopez, N. Lopez-Muñoz, A. Chari, S. Dorado, S. Barrio, S. Arora, A. Kumar, A. Chung, T. Martin, J. Wolf

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Reverse Correlation Uncovers More Complete Tinnitus Spectra

    Reverse Correlation Uncovers More Complete Tinnitus Spectra oleh Alec Hoyland, Nelson V. Barnett, Benjamin W. Roop, Danae Alexandrou, Myah Caplan, Jacob Mills, Benjamin Parrell, Divya A. Chari, Adam C. Lammert

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Current Trends, Controversies, and Future Directions in the Evaluation and Management of Superior Canal Dehiscence Syndrome

    Current Trends, Controversies, and Future Directions in the Evaluation and Management of Superior Canal Dehiscence Syndrome oleh Kristine Elisabeth Eberhard, Kristine Elisabeth Eberhard, Divya A. Chari, Hideko Heidi Nakajima, Mads Klokker, Mads Klokker, Per Cayé-Thomasen, Per Cayé-Thomasen, Daniel J. Lee

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Interprofessional Climate Change Curriculum in Health Professional Programs: A Scoping Review

    Interprofessional Climate Change Curriculum in Health Professional Programs: A Scoping Review oleh Trisha Dalapati, Sophie E. Nick, Tristan A. Chari, Ian A. George, Alexandra Hunter Aitchison, Mark P. MacEachern, Aine N. O’Sullivan, Kreager A. Taber, Andrew Muzyk

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001

    EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARIS... oleh X. Leleu, M. Beksac, T. Chou, M.A. Dimopoulos, S. Yoon, H.M. Prince, A. Chari, A. Oriol, D.S.D. Siegel, M. Khurana, M. Qi, M. Obreja, L. Pour, T. Shelekhova

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

    PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA oleh A. Krishnan, A. K. Nooka, A. Chari, A. Garfall, T. Martin, S. Nair, X. Lin, K. Qi, A. Londhe, L. Pei, E. Ammann, R. Kobos, J. Smit, T. Parekh, M. Slavcev, S. Usmani

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS

    P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN D... oleh K. Weisel, A. Chari, S. Z. Usmani, H. Goldschmidt, M.-V. Mateos, K. Qi, A. Londhe, S. Nair, X. Lin, L. Pei, E. Ammann, R. Kobos, J. Smit, T. Parekh, M. Slavcev, P. Moreau

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) CD3 BISPECIFIC ANTIBODY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 STUDY RESULTS

    TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) CD3 BISPECIFIC ANTIBODY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 STUDY RESULTS oleh JG Berdeja, AY Krishnan, A Oriol, NWV Donk, P Rodríguez-Otero, E Askari, M Mateos, MC Minnema, LJ Costa, R Verona, BW Hilderq, S Girgisq, T Prior, JS Russell, JD Goldberg, A Chari

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    P876: INCIDENTAL DISCOVERY OF PROBABLE PATHOGENIC GERMLINE VARIANTS IN MULTIPLE MYELOMA PATIENTS UNDERGOING SOMATIC GENOMIC PROFILING

    P876: INCIDENTAL DISCOVERY OF PROBABLE PATHOGENIC GERMLINE VARIANTS IN MULTIPLE MYELOMA PATIENTS UNDERGOING SOMATIC GENOMIC PROFILING oleh S. Thibaud, T. Brander, M. Balwani, T. Mouhieddine, D. Melnekoff, O. Van Oekelen, A. Lagana, J. Houldsworth, A. Chari, J. Richter, L. Sanchez, S. Richard, C. Rodriguez, A. Rossi, H. J. Cho, S. Jagannath, K. Onel, S. Parekh

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    S182: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM MONUMENTAL-1

    S182: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED EFFICACY AND SAFETY RESULTS FR... oleh M. C. Minnema, A. Krishnan, J. G. Berdeja, A. Oriol, N. W. van de Donk, P. Rodríguez-Otero, D. Morillo, M.-V. Mateos, L. J. Costa, J. Caers, D. Vishwamitra, J. Ma, S. Yang, B. W. Hilder, J. Tolbert, J. D. Goldberg, A. Chari

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS FROM MONUMENTAL-1

    P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RE... oleh N. W. C. J van de Donk, M C Minnema, J G Berdeja, A Oriol, A Krishnan, P Rodríguez-Otero, E Askari, M Mateos, L. J Costa, R Verona, J Ma, S Girgis, S Yang, B. W Hilder, J Russell, J. D Goldberg, A Chari

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL

    P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP... oleh T. Facon, T. Plesner, S. Usmani, S. Kumar, N. Bahlis, C. Hulin, R. Orlowski, H. Nahi, P. Mollee, K. Ramasamy, M. Roussel, A. Jaccard, M. Delforge, L. Karlin, B. Arnulf, A. Chari, H. Pei, N. Gupta, S. Kaila, K. Matt, K. Gries, R. Carson, F. Borgsten, K. Weisel, A. Perrot

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL

    P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL oleh A. Nooka, A. Cohen, H. Lee, A. Badros, A. Suvannasankha, N. Callander, A. Abdallah, S. Trudel, A. Chari, E. Libby, M. Chaudhry, M. Hultcrantz, K.M. Kortüm, P. Richardson, R. Popat, D. Sborov, S. Hakim, E. Lewis, B. Bhushan, B. Gorsh, I. Gupta, J. Opalinska, S. Lonial

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1

    P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC... oleh J. Martínez-López, P. Moreau, S. Z. Usmani, A. Garfall, N. W. van de Donk, J. F. San-Miguel, A. Oriol, A. Chari, L. Karlin, M.-V. Mateos, R. Popat, A. K. Nooka, S. Sidana, D. Trancucci, R. Verona, S. Girgis, C. Uhlar, T. Stephenson, A. Banerjee, A. Krishnan

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN

    P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE N... oleh C. Rodriguez, J. L. Kaufman, J. Laubach, D. W. Sborov, B. Reeves, A. Chari, R. Silbermann, L. J. Costa, L. D. Anderson, Jr, N. Nathwani, N. Shah, N. Bumma, A. Jakubowiak, R. Z. Orlowski, H. Pei, A. Cortoos, S. Patel, T. S. Lin, P. G. Richardson, P. M. Voorhees

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: